Here's Why This Top Stock Is a Buy on the Dip

·4-min read
Here's Why This Top Stock Is a Buy on the Dip

Novavax (NASDAQ: NVAX) was last year's stock-market star, with gains of more than 2,000%. The biotech company impressed investors as it brought its coronavirus vaccine candidate through clinical trials and won $1.6 billion in investment from the U.S. government. Rivals Pfizer and Moderna have fully vaccinated more than 30% of Americans...while Novavax remains on the sidelines.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting